About FDA
Cumulative number of technical analyses of postmarket device problems and performance completed
Cumulative FY 2012 Target: 131 by 9/30/2012
Dictionary: Postmarket device problems and performance issues constitute one of CDRH’s primary public health priorities. Typically, the appearance of such problems begins with many ambiguities and gaps in understanding exactly what happened in the reported incident(s) and, more importantly, why. The technical analyses are used to assess the hazards, determine the adequacy of proposed corrective actions, determine appropriate test methods, and develop case strategies for reported problems.
Information is current as of December 31, 2012
Fiscal Year - 2012
Cumulative FY 2012 Target: 131 by 9/30/2012
| Time | Cumulative Annual Target | Cumulative Number |
|---|---|---|
| Oct 2011 | 131 | 13 |
| Nov 2011 | 131 | 25 |
| Dec 2011 | 131 | 29 |
| Jan 2012 | 131 | 41 |
| Feb 2012 | 131 | 47 |
| Mar 2012 | 131 | 56 |
| Apr 2012 | 131 | 61 |
| May 2012 | 131 | 67 |
| Jun 2012 | 131 | 81 |
| Jul 2012 | 131 | 91 |
| Aug 2012 | 131 | 100 |
| Sep 2012 | 131 | 106 |
FY 2012 Cumulative Total: 106
Number of technical analyses of postmarket device problems and performance completed during the month
Cumulative FY 2012 Target: 131 by 9/30/2012
Fiscal Year - 2012
Cumulative FY 2012 Target: 131 by 9/30/2012
| Time | Target | Number |
|---|---|---|
| Oct 2011 | N/A | 13 |
| Nov 2011 | N/A | 12 |
| Dec 2011 | N/A | 4 |
| Jan 2012 | N/A | 12 |
| Feb 2012 | N/A | 6 |
| Mar 2012 | N/A | 9 |
| Apr 2012 | N/A | 5 |
| May 2012 | N/A | 6 |
| Jun 2012 | N/A | 14 |
| Jul 2012 | N/A | 10 |
| Aug 2012 | N/A | 9 |
| Sep 2012 | N/A | 6 |
FY 2012 Total: 106
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
